Codiak BioSciences, Inc.

Codiak Bioscience
Codiak Bioscience
Company Information
Company Description

Codiak is a clinical-stage biopharmaceutical company focused on the development of exosome-based therapeutics, a class of medicines that treat a wide spectrum of diseases with high unmet medical need. Codiak has utilized its proprietary engEx™ Platform to generate engineered exosomes aimed at treating a broad range of diseases, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Industries
Biotechnology, Medical, Therapeutics

Please note, it is important to assess the company’s business activities against Section 1202(e)(3) which specifies certain industries that are not considered a “qualified trade or business.”

Entity Type
C Corporation

A C corporation is a qualified legal entity for QSBS.

Incorporation Date

2015

Incorporation State
California
Qualified Small Business Stock (QSBS) Details

Exemption Level

Given the Company was incorporated after September 27, 2010, all shares could be eligible for up to a 100% tax exclusion if the other QSBS criteria are met.

Any individual owning stock purchased or received directly from the company could potentially be eligible for the QSBS capital gains tax exclusion or the Section 1045 gain rollover if the QSBS standards as per IRC Section 1202 were met at the time of issuance.

In order to assess whether stock issued previously may qualify, the Company would also have to have not taken actions that invalidate QSBS status such as a certain level of redemptions, and would have to satisfy the active business requirement.

Do you hold stock in this company?

Validate QSBS Eligibility
IPO Details
IPO Date
Symbol
CDAK
IPO Raised
$82,500,000.00
IPO Price
$15.00
IPO Date Adjusted Closing Price
$12.12

This article does not constitute legal or tax advice. Please consult with your legal or tax advisor with respect to your particular circumstance.